Tranexamic acid tablets

There are various natural antagonists of plasmin (ogen) in the blood circulation, such as antiplasmin. Under normal circumstances, the antifibrinolytic activity in the blood is many times higher than the fibrinolytic activity, so fibrinolytic bleeding does not occur. However, these antagonists cannot block the activation of activators (such as urokinase, etc.) adsorbed on the fibrin network to form plasmin. Plasmin is a kind of endopeptidase that can cleave the arginine and lysine peptide chains of fibrin (ogen) in a neutral environment to form fibrin degradation products and cause blood clot dissolution and bleeding. Plasminogen is specifically adsorbed on fibrin through the lysine binding site in its molecular structure. Lysine can competitively inhibit this adsorption, reduce the adsorption rate of plasminogen, and thus reduce the activation process of plasminogen.

The chemical name of this product is: (E)-4-aminomethylcyclohexanecarboxylic acid

This product is white tablets.

This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product should be used with caution before heparinization. This product is also suitable for: ① traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid glands, and liver; ② used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; ③ fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism; ④ menorrhagia, hyphema, and severe epistaxis due to local increased fibrinolysis; ⑤ used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophiliacs with factor VIII or factor IX deficiency; ⑥ central artery

Oral administration: 1-1.5 g at a time, 2-6 g per day. To prevent bleeding before and after surgery, refer to the above dosage. To treat bleeding caused by primary fibrinolysis, the dosage can be increased as appropriate.

This product has fewer side effects than 6-aminocaproic acid. Occasionally, drug overdose may cause intracranial thrombosis and bleeding. Other side effects include diarrhea, nausea and vomiting; less common are menstrual discomfort (caused by blood coagulation during menstruation). Patients who must continue to use this product for a long time should undergo ophthalmological examinations and monitoring (such as vision tests, vision, visual field and fundus).

① It is incompatible with thrombolytic agents such as penicillin or urokinase; ② The combination of oral contraceptives, estrogen or prothrombin complex concentrates with this product may increase the risk of thrombosis.

Keep in a light-proof and airtight container.

0.125g

Zhengzhou Fusheng Pharmaceutical Co., Ltd.

• Founded in:

  2004-03-23

• Address:

  No. 34, Dongqing Street, Zhengzhou High-tech Zone

• Tax NO.:

  91410100760211601W

• Registered Funds:

  31 million yuan

• Email:

  Log in to view